Department of Urology, University of Louisville, Louisville, KY.
Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY.
Transl Res. 2021 May;231:92-101. doi: 10.1016/j.trsl.2020.11.014. Epub 2020 Dec 3.
Currently, clinicians rely on clinical nomograms to stratify progression risk at the time of diagnosis in patients with prostate cancer (CaP). However, these tools may not accurately distinguish aggressive potential in low-grade CaP. The current study determined the diagnostic potential of 3 molecular markers (ROCK1, RUNX3, and miR-301a) in terms of their ability to identify which low-grade tumors are likely to progress. Real-time PCR and immunohistochemical analysis were used to assess ROCK1, RUNX3, and miR-301a expression profiles in 118 serum and needle biopsy specimens. Expressions of ROCK1 and miR-301a were found to be significantly higher in Gleason 6 and 7 CaP as compared to BPH, while an inverse trend was observed with RUNX3. Further, incorporation of all 3 molecular markers significantly improved clinical nomograms' diagnostic accuracy and correlated with disease progression. Hence, in conclusion, the inclusion of these 3 molecular markers identified aggressive phenotype and predicted disease progression in low-grade CaP tumors at the time of diagnosis.
目前，临床医生依赖临床列线图在前列腺癌 (CaP) 患者诊断时对进展风险进行分层。然而，这些工具可能无法准确区分低级别 CaP 的侵袭潜力。本研究通过评估其识别哪些低级别肿瘤可能进展的能力，确定了 3 个分子标志物（ROCK1、RUNX3 和 miR-301a）在诊断中的潜力。实时 PCR 和免疫组织化学分析用于评估 118 份血清和针吸活检标本中的 ROCK1、RUNX3 和 miR-301a 表达谱。与 BPH 相比，ROCK1 和 miR-301a 的表达在 Gleason 6 和 7 CaP 中明显更高，而 RUNX3 的表达则相反。此外，所有 3 个分子标志物的纳入均显著提高了临床列线图的诊断准确性，并与疾病进展相关。因此，综上所述，这些 3 个分子标志物的纳入可识别低级别 CaP 肿瘤在诊断时的侵袭表型并预测疾病进展。
